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Because it is impossible to assess in vitro or in vivo the toxicity of all nanoparticles available on the market on a case-by-case basis, computational approaches have been proposed as useful alternatives to predict in silico the hazard potential of engineered nanoparticles. Despite promising results, a major issue associated with these mathematical models lies in the a priori choice of the physico-chemical descriptors and the biological endpoints. We performed a thorough bibliographic survey on the biological endpoints used for nanotoxicology purposes and compared them between experimental and computational approaches. They were found to be disparate: while conventional in vitro nanotoxicology assays usually investigate a large array of biological effects using eukaryotic cells (cytotoxicity, pro-inflammatory response, oxidative stress, genotoxicity), computational studies mostly focus on cell viability and also includes studies on prokaryotic cells. We may thus wonder the relevance of building complex mathematical models able to predict accurately a biological endpoint if this latter is not the most relevant to support human health risk assessment. The choice of biological endpoints clearly deserves to be more carefully discussed. This could bridge the gap between experimental and computational nanotoxicology studies and allow in silico predictive models to reach their full potential.
In the field of nanotoxicology a major aim is the investigation of the biological effects induced by engineered nanoparticles to determine their potential impact on the environment and human health. In this context, in vivo studies are potentially the most informative as animal models reproduce a physiological integrated response. But because of ethical issues, animal experiments are limited to follow the 3R's rule defined by Russell and Burch 1 aiming to replace, reduce and refine the use of animals for scientific purposes. This trend was followed by regulation 2 which advocates for the reduction of animal models for evaluating nanoparticles toxicity. In vitro models have then been developed for human risk assessment. They possess several advantages such as being inexpensive, easy and rapid to perform, but most of all they allow the high throughput screening of biological effects triggered by nanoparticles, also enabling mechanistic studies. In this context, a large panel of assays is usually carried out to determine the cytotoxicity, the pro-inflammatory response, the oxidative stress or the genotoxicity triggered by the contact of nanoparticles with eukaryotic cells 3-6 (some examples are reported in Table 1 , even though there are no standardized methods and no international guidelines). However, because of the multitude and variety of engineered nanoparticles we are increasingly exposed to it is impossible to assess empirically (in vitro or in vivo) their safety 7 . To avoid long, complex and costly experimental assays, computational modeling has been proposed as a useful alternative to predict in silico the hazard potential of engineered nanoparticles to human health. Initially developed in the 1960s to be applied on small series of congeneric compounds using relatively simple regression methods, nowadays the computational approaches allow to analyze very large datasets comprising thousands of diverse chemical structures using a wide variety of statistical and machine learning techniques 8 . In the last decade, some computational 6 approaches have been applied to nanoparticles such as (Q)SAR ((Quantitative) Structure Activity Relationship) [9] [10] [11] [12] [13] , read-across [14] [15] [16] [17] , neural network 18 or decision tree 19 classifications.
These models can theoretically be built using data obtained through either in vitro or in vivo assays. But in practice, to be reliable, these models should involve a very large amount of data.
And it is thus difficult to get such an amount of data with in vivo experiments. Indeed, while in vivo experiments are supposed to be closer to "real life" condition because they take into account physiological parameters, they are expensive, time-consuming and limited because of ethical issues. On the contrary, in vitro studies seem more suitable as they are cheaper, more rapid and easier to perform. They are thus rather useful for mechanistic studies and as screening tools as they allow to collect more information. This doesn't mean that in vivo studies are less qualified to help assess risks, but it argues for considering a multi-step process research. First, in vitro assays could be used for the screening of the nanomaterials that are worth investigating further. Based on these data predictive models could be built for risk assessment. And finally particles of interest could be further investigated using in vivo assays that can bring complementary information.
In silico models are the subject of intensive research and are highly topical issues. An overview of the landscape of the available computational models for nanomaterials has been very recently reported 20 . Although some of these mathematical models have produced promising results, their construction is associated with some challenges and questions. A major issue lies in the a priori choice of the physico-chemical descriptors and biological endpoints, which are at the core of the computational modeling. As the QSAR approach remains the most abundantly documented in the literature we will focus our discussion on it thereafter. It was originally developed for risk assessment of chemicals for which many molecular descriptors are available in chemical database or easily calculated with usual softwares. Nanoparticles, because of their specific properties, need to be described by additional parameters accurately experimentally measured such as size, shape, surface area, surface reactivity, crystalline structure, composition of core and coating, etc. 21 . Therefore, one of the specific features of QSAR modeling for nanotoxicology purposes involves a labor-intensive, time-consuming and costly effort to obtain these "nanodescriptors". And because descriptors are mathematical representations of relevant properties of nanoparticles, nanoparticle physico-chemical features should be carefully considered, especially the parameters recommended by the ISO/TR13014:2012 standard 22 .
Unfortunately, a systematic and comprehensive nanoparticle physico-chemical characterization is not always available in the proposed nanoQSAR models. Furthermore, the reality is much more complex and to take into account the "biological identity" of the nanoparticles (reflecting their complex interactions with biological environments) the presence and nature of the corona formed around the nanoparticles should be introduced in the equation [23] [24] [25] .
Regarding the choice of the biological endpoints to be predicted thanks to the model, the question is even more debatable. Indeed, we observed that often, the main biological endpoints that are used in empirical nanotoxicology studies (studies without any modelling purpose) and
in studies dedicated to the in silico prediction of the nanoparticle toxicity are different. We thus wondered why there is such a discrepancy between the two types of studies. The assays used for empirical nanotoxicology reported in Table 1 can all be a priori used for modelling. But because many other parameters are involved such as the particle type, the cell type, etc… they will not exhibit the same efficiency in their predictive potential for risk assessment. No one could predict which assays (and why) will be more predictive than others. Only the construction of the models will tell if they work or not. To exemplify this point, we performed a literature survey focused on nanoparticles (including nanomaterials and nanostructure) and QSAR model and its variants (because as mentioned before, QSAR approach is among the most abundantly documented and used computational approaches). As illustrated in Figure 1 We then analyzed more closely the studies using eukaryotic cells. We especially paid attention to the quantity and quality of the data needed to build the mathematical models, 2 criteria that are commonly acknowledged to be of high importance for the construction of reliable QSAR models. In addition, we examined the number and nature of the selected biological endpoints.
Regarding the first criteria about data quantity (i.e. the size of the dataset), as mentioned before QSAR models were originally developed for chemicals for which data were easily available and QSAR could be built based on considerably large databases (compounds in the order of hundreds or even thousands). On the contrary, in the case of nanoparticles, due to the difficulty to gather physico-chemical and biological data in standardized conditions, datasets are often very small (units or tens, in the best case) 34 . In our bibliographic survey, we found that most of the studies used a dataset higher than 20 but at the expense of the quality of the data.
Indeed, for standard in vitro nanotoxicology, the ISO/TR13014:2012 standard recommends to characterize at least the 8 following nanoparticle physico-chemical features:
agglomeration/aggregation state, composition, size, shape, solubility/dispersibility, specific surface area, density of surface groups and surface chemistry 22 . But in computational studies this comprehensive nanoparticle physico-chemical characterization is far from being systematic. Actually, none of the 40 papers experimentally measured these 8 crucial parameters.
The nanodescriptors greatly varied depending on the studies, some considered only nanoparticle size and zeta potential while others included much more parameters calculated or experimentally assessed but none characterized the 8 parameters recommended by the ISO/TR13014:2012 standard. The lack of complete characterization may be explained by some metrological issues. First, sample preparation is not trivial for techniques requiring a good dispersion in suspensions. In addition, some questions are still open. For instance, the agglomeration/aggregation state is quite unclear. Agglomeration and aggregation are very different concepts: in agglomerates particles are just gathered by weak interactions and agglomerates size is expected to change a lot during a journey in living organisms, whereas in aggregates particles are cemented by solid bridges and will not budge. So there is a high risk that agglomerates size measurement does not make much sense, unless the medium and sample preparation is representative of biological conditions. As far as size is concerned, even in the case of well dispersed spherical particles -defined by one parameter-the correct measurement of a size distribution is all but trivial, and direct methods as TEM or indirect methods as DLS give different results. Things get even more complicated when shape is not spherical and at least a second dimensional parameter is needed to describe particles. Density of surface groups and surface chemistry may be determined in average, but locally they depend on crystal exposed faces or even edges, which supposes expensive HRTEM studies for a perfect description.
Finally, on the third criteria regarding the biological endpoints, we observed that in the vast majority of the cases (29/40 papers) only one biological endpoint was considered, mainly cell viability. While as mentioned before, in standard in vitro nanotoxicology before concluding on the toxicity of a nanoparticle several parameters should be investigated (i.e. cytotoxicity, proinflammatory response, oxidative stress, genotoxicity, etc.). In this respect, the study from
Maher et al. 55 was the most complete as in addition to cytotoxicity, reactive oxygen species and pro-inflammatory cytokine production were included as biological endpoints. Similarly, Le et al. 47 considered the oxidative stress in their computational study.
In the end, none of the 40 papers met the 3 criteria (dataset>20; physico-chemical characterization as recommended by ISO/TR13014:2012 standard; and more than one biological endpoint studied), 10 met 2, 20 only one and 10 not even one.
Therefore, there is a gap between the nanodescriptors and biological endpoints used in computational approaches and in vitro empirical testing for human health risk assessment.
Taken together these observations argue for the need to discuss the relevance of the selected biological endpoints. Such discussion could bridge the gap between experimental and computational nanotoxicology studies to get predictive models more useful for human risk assessment. It should be also interesting to consider and include in nanoQSAR alternative biological parameters which could be more relevant to take into account nanoparticle doseeffects such as NOAEL (No Observable Adverse Effect Level, i.e. the highest tested nanoparticle dose at which no adverse effect is found where higher doses result in an adverse effect).
It is unanimously acknowledged that many challenges in predictive nanotoxicology are associated with the quantity and quality of the data needed to build the mathematical model.
But the nature of the biological endpoints deserves better attention and should be carefully discussed to get more useful and applicable models to support human risk assessment. This way, mathematical models could reach their full potential, able to predict nanoparticle toxicity avoiding empirical assays, saving time, money and animal experiments.
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